Merus NV
MRUS95.160USD
-0.020-0.02%
收盘 11/06, 16:00（美东）报价延迟15分钟
7.22B总市值
亏损市盈率 TTM
关于 Merus NV 公司
Merus NV 是一家总部位于荷兰的生物技术公司，专注于为癌症患者开发差异化疗法。Merus 的产品线基于 Multiclonics 格式。其产品旨在与多个靶标结合，并具有抗癌作用，可对抗驱动癌症的复杂机制。该公司的产品利用技术平台与癌症抗原结合，并利用免疫系统的力量杀死肿瘤细胞。其中一种药物 zenocutuzumab (Zeno) 是一种 Biclonics 抗体，专注于帮助肺癌、胰腺癌和其他类型实体瘤患者。该公司在荷兰和美国开展业务。
Merus NV简介
公司代码MRUS
公司名称Merus NV
上市日期May 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
员工数量260
证券类型Ordinary Share
年结日May 19
公司地址Yalelaan 62
城市UTRECHT
上市交易所NASDAQ Global Market Consolidated
国家Netherlands
邮编3584 CM
电话310302538800
网址https://merus.nl/
公司代码MRUS
上市日期May 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
Merus NV公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
8.20%
Paradigm BioCapital Advisors LP
5.65%
RTW Investments L.P.
5.27%
Wellington Management Company, LLP
4.91%
Commodore Capital LP
4.65%
其他
71.32%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
8.20%
Paradigm BioCapital Advisors LP
5.65%
RTW Investments L.P.
5.27%
Wellington Management Company, LLP
4.91%
Commodore Capital LP
4.65%
其他
71.32%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
36.78%
Hedge Fund
34.50%
Investment Advisor
25.54%
Corporation
1.93%
Venture Capital
1.77%
Research Firm
1.13%
Private Equity
0.93%
Individual Investor
0.37%
Pension Fund
0.36%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
431
77.28M
101.92%
-5.29M
2025Q2
411
75.46M
99.77%
-10.50M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
2023Q2
260
49.90M
100.83%
+114.35K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
6.22M
8.2%
+593.98K
+10.56%
Jun 30, 2025
Paradigm BioCapital Advisors LP
4.28M
5.65%
+727.89K
+20.48%
Jun 30, 2025
RTW Investments L.P.
4.00M
5.28%
-168.84K
-4.05%
Jun 30, 2025
Wellington Management Company, LLP
3.73M
4.92%
-991.45K
-21.01%
Jun 30, 2025
Commodore Capital LP
3.52M
4.65%
-947.84K
-21.19%
Jun 30, 2025
Deerfield Management Company, L.P.
3.38M
4.47%
+210.70K
+6.64%
Jun 30, 2025
Avoro Capital Advisors LLC
3.16M
4.16%
+155.56K
+5.19%
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.26M
2.98%
+1.17M
+106.44%
Jun 30, 2025
Holocene Advisors, LP
2.23M
2.94%
+351.62K
+18.77%
Jun 30, 2025
Westfield Capital Management Company, L.P.
2.04M
2.69%
+541.17K
+36.05%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Harbor Health Care ETF
4.61%
ALPS Medical Breakthroughs ETF
4.1%
Tema Oncology ETF
3.91%
AltShares Merger Arbitrage ETF
3.3%
NYLI Merger Arbitrage ETF
3.1%
Goldman Sachs Hedge Industry VIP ETF
2.89%
First Trust IPOX Europe Equity Opportunities ETF
2.59%
Simplify Health Care ETF
2.48%
Invesco Dorsey Wright Healthcare Momentum ETF
1.5%
AltShares Event-Driven ETF
1.39%
查看更多
Harbor Health Care ETF
占比4.61%
ALPS Medical Breakthroughs ETF
占比4.1%
Tema Oncology ETF
占比3.91%
AltShares Merger Arbitrage ETF
占比3.3%
NYLI Merger Arbitrage ETF
占比3.1%
Goldman Sachs Hedge Industry VIP ETF
占比2.89%
First Trust IPOX Europe Equity Opportunities ETF
占比2.59%
Simplify Health Care ETF
占比2.48%
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.5%
AltShares Event-Driven ETF
占比1.39%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
